Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community

Movement Disorders

Volumn 31, Issue 9, 2016, Pages 1405-1408

  Mahlknecht, Philipp ^a,b   Gasperi, Arno ^c   Willeit, Peter ^a,d,e   Kiechl, Stefan ^a   Stockner, Heike ^a   Willeit, Johann ^a   Rungger, Gregorio ^c   Sawires, Martin ^a   Nocker, Michael ^a   Rastner, Verena ^a   Mair, Katherina J ^a   Hotter, Anna ^a   Poewe, Werner ^a   Seppi, Klaus ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Hospital of Bruneck   (Italy)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

mild parkinsonian signs (MPS); olfactory dysfunction; probability; probable prodromal Parkinson's disease; transcranial sonography (TCS)

Indexed keywords

ADULT; AGED; ARTICLE; FAMILY HISTORY; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MEDICAL SOCIETY; PARKINSON DISEASE; PARKINSONISM; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PRODROMAL SYMPTOM; RESEARCH DIAGNOSTIC CRITERIA; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA;

EID: 84985930523     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26674     Document Type: Article

References (12)

1. Stern MB, Lang A, Poewe W. Toward a redefinition of Parkinson's disease. Mov Disord 2012;27:54-60.
2. Berg D, Postuma RB, Bloem B, et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord 2014;29:454-462.
3. Mahlknecht P, Seppi K, Poewe W. The Concept of Prodromal Parkinson's Disease. J Parkinsons Dis 2015;5:681-697.
4. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson's disease. Mov Disord 2015;30:1600-1611.
5. Mahlknecht P, Seppi K, Stockner H, et al. Substantia nigra hyperechogenicity as a marker for parkinson's disease: A population-based study. Neurodegener Dis 2013;12:212-218.
6. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
7. Hummel T, Konnerth CG, Rosenheim K, Kobal G. Screening of olfactory function with a four-minute odor identification test: reliability, normative data, and investigations in patients with olfactory loss. Ann Otol Rhinol Laryngol 2001;110:976-981.
8. Wenning GK, Kiechl S, Seppi K, et al. Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. Lancet Neurol 2005;4:815-820.
9. Berg D, Godau J, Seppi K, et al. The PRIPS study: Screening battery for subjects at risk for Parkinson's disease. Eur J Neurol 2013;20:102-108.
10. Berg D, Marek K, Ross GW, Poewe W. Defining at-risk populations for Parkinson's disease: lessons from ongoing studies. Mov Disord 2012;27:656-665.
11. Postuma RB, Gagnon J-F, Bertrand J-A, Génier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 2015;84:1104-1113.
12. Mahlknecht P, Iranzo A, Högl B, et al. Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. Neurology 2015;84:654-658.